Identification of genes down-regulated during lung cancer progression: A cDNA array study

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Campioni, Mara ^a   Ambrogi, Vincenzo ^b   Pompeo, Eugenio ^b   Citro, Gennaro ^c   Castelli, Mauro ^c   Spugnini, Enrico P ^c   Gatti, Antonio ^b   Cardelli, Pierluigi ^c   Lorenzon, Laura ^d   Baldi, Alfonso ^a   Mineo, Tommaso C ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DECORIN; SCLEROPROTEIN; STROMELYSIN 3;

ANGIOGENESIS; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETINOBLASTOMA; SEX DIFFERENCE; TUMOR SUPPRESSOR GENE; COMPARATIVE STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 52949090360     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-38     Document Type: Article

References (39)

1. Molecular pathogenesis of lung cancer. S Zochbauer-Muller AF Gazdar JD Minna, Annu Rev Physiol 2002 64 681 708 10.1146/annurev.physiol.64.081501.155828 11826285
2. Predicting the sites of metastases from lung cancer using molecular biologic markers. TA D'Amico TA Aloia MB Moore DH Conlon JE Herndon 2nd MS Kinch DH Harpole Jr, Ann Thorac Surg 2001 72 1144 1148 10.1016/S0003-4975(01)02979-4 11603427
3. Stage I non small cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. DH Harpole Jr JE Herndon 2nd WG Young Jr WG Wolfe DC Sabiston Jr, Cancer 1995 76 787 796 10.1002/1097-0142(19950901)76: 5<787::AID-CNCR2820760512>3.0.CO;2-Q 8625181
4. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. R Feld LV Rubinstein TH Weisenberger, J Clin Oncol 1984 2 1352 1358 6512581
5. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. TA D'Amico M Massey JE Herndon 2nd MB Moore DH Harpole Jr, J Thorac Cardiovasc Surg 1999 117 736 743 10.1016/S0022-5223(99)70294-1 10096969
6. Prognostic factors in clinical stage I non-small cell lung cancer. K Suzuki K Nagai J Yoshida E Moriyama M Nishimura K Takahashi Y Nishiwaki, Ann Thorac Surg 1999 67 927 932 10.1016/S0003-4975(99)00140-X 10320230
7. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. D Liu C Huang K Kameyama E Hayashi A Yamauchi S Kobayashi H Yokomise, Ann Thorac Surg 2001 71 949 955 10.1016/S0003-4975(00)02545-5 11269479
8. Molecular biologic substaging of stage I lung cancer according to gender and histology. TA D'Amico TA Aloia MB Moore JE Herndon 2nd KR Brooks CL Lau DH Harpole Jr, Ann Thorac Surg 2000 69 882 886 10.1016/S0003-4975(99)01522-2 10750777
9. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. DR Shopland, Environ Health Perspect 1995 103 131 142 8741773 10.2307/3432300
10. Prognostic value of p53 in non small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. V Esposito A Baldi A De Luca G Mazzarella P Micheli F Baldi M Caputi A Giordano, Human Path 1997 28 233 237 10.1016/S0046-8177(97)90112-X 9023408
11. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small lung cancer. V Esposito A Baldi A De Luca AM Groeger M Loda GG Giordano M Caputi F Baldi M Pagano A Giordano, Cancer Res 1997 57 3381 3385 9270000
12. p21 expression in non-small cell lung cancer: relationship to survival. M Caputi V Esposito A Baldi A De Luca C Dean G Signoriello F Baldi A Giordano, Am J Respir Cell Mol Biol 1998 18 213 217 9476908
13. Expression of p21 in non-small cell lung cancer: relationship with PCNA. AM Groeger M Caputi V Esposito A Baldi R Rossiello D Santini A Mancini HE Kaiser F Baldi, Anticancer Res 2000 20 3301 3306 11062757
14. Differential expression of Rb2/p130 and p107 in normal human tissue and primary lung cancer. A Baldi V Esposito A De Luca Y Fu I Meoli GG Giordano M Caputi F Baldi A Giordano, Clin Cancer Res 1997 3 1691 1697 9815552
15. Analysis of Fas (Apo-1/CD95) expression in non-small-cell lung cancer. V Esposito A Baldi G Liuzzi G Tonini B Vincenzi P Persichetti M Santini V Ambrogi TC Mineo V Montesarchio E Wolner F Baldi AM Groeger, Anticancer Res 2003 23 4901 4905 14981943
16. Prognostic value of immunohistochemical expression of p53, BAX, BCL-2 and BCL-Xl in resected non small cell lung cancer. AM Groeger V Esposito A De Luca R Cassandro G Tonini V Ambrogi F Baldi R Goldfarb TC Mineo A Baldi E Wolner, Histopathology 2004 44 54 63 10.1111/j.1365-2559.2004.01750.x 14717670
17. Cell cycle related proteins as prognostic parameters in radically resected non small cell lung cancer (NSCLC). V Esposito A Baldi A De Luca G Tonini B Vincenzi D Santini P Persichetti A Mancini G Citro F Baldi AM Groeger M Caputi, J Clin Pathol 2005 58 734 739 15976342 10.1136/jcp.2004.023531
18. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. TC Mineo V Ambrogi A Baldi C Rabitti P Bollero B Vincenzi G Tonini, J Clin Pathol 2004 57 591 597 15166262 10.1136/jcp.2003.013508
19. Analysys of HtrA1 serine protease expression in human lung cancer. V Esposito M Campioni A De Luca EP Spugnini F Baldi R Cassandro A Mancini B Vincenzi A Groeger M Caputi A Baldi, Anticancer Res 2006 26 3455 3460 17094466
20. Identification of genes down-regulated during melanoma progression: a cDNA array study. A Baldi T Battista A De Luca D Santini R Rossiello F Baldi PG Natali D Lombardi M Picardo A Felsani MG Paggi, Exp Dermatol 2003 12 213 218 10.1034/j.1600-0625.2003.00026.x 12702151
21. Cell cycle alterations and lung cancer. B Vincenzi G Schiavon M Villetta D Santini G Perrone M Di Marino S Angeletti A Baldi G Tonini, Histol Histopathol 2006 21 423 435 16437388
22. Relation of neovascularization to metastasis of non-small cell lung cancer. P Macchiarini G Fontanini MJ Hardin F Squartini CA Angeletti, Lancet 1992 340 145 146 10.1016/0140-6736(92)93217-B 1378165
23. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. T Yano S Tanikawa T Fujie M Masutani T Horie, Eur J Cancer 2000 36 601 609 10.1016/S0959-8049(99)00327-5 10738124
24. Patterns of angiogenesis in non-small-cell lung carcinoma. BV Offersen P Pfeiffer S Hamilton-Dutoit J Overgaard, Cancer 2001 91 1500 1509 10.1002/1097-0142(20010415)91:8<1500::AID-CNCR1158>3.0.CO;2-M 11301398
25. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. M Kurayoshi N Oue H Yamamoto M Kishida A Inoue T Asahara W Yasui A Kikuchi, Cancer Res 2006 66 10439 10448 10.1158/0008-5472.CAN-06-2359 17079465
26. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. M Jönsson J Dejmek PO Bendahl T Andersson, Cancer Res 2002 62 409 416 11809689
27. The complex pathways of Wnt 5a in cancer progression. T Pukrop C Binder, J Mol Med 2008 86 259 266 10.1007/s00109-007-0266-2 17952396
28. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. A Karameris P Panagou T Tsilalis D Bouros, Am J Respir Crit Care Med 1997 156 1930 1936 9412577
29. Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer. TJ Delebecq H Porte F Zerimech MC Copin V Gouyer E Dacquembronne M Balduyck A Wurtz G Huet, Clin Cancer Res 2000 6 1086 1092 10741738
30. The retinoblastoma protein family in cell cycle and cancer. MG Paggi A Baldi F Bonetto A Giordano, J Cell Biochem 1996 62 418 430 10.1002/(SICI)1097- 4644(199609)62:3<418::AID-JCB12>3.0.CO;2-E 8872613
31. Cell-cycle molecules in mesothelioma, an overview. EP Spugnini M Campioni A D'Avino G Caruso G Citro A Baldi, J Exp Clin Cancer Res 2007 26 515 521 18365547
32. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. VA Potiron G Sharma P Nasarre JA Clarhaut HG Augustin RM Gemmill J Roche HA Drabkin, Cancer Res 2007 67 8708 8715 10.1158/0008-5472.CAN-06-3612 17875711
33. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. S Kusy P Nasarre D Chan V Potiron D Meyronet RM Gemmill B Constantin HA Drabkin J Roche, Neoplasia 2005 7 457 465 15967098 10.1593/neo.04721
34. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. E Castro-Rivera S Ran P Thorpe JD Minna, Proc Natl Acad Sci USA 2004 101 11432 11437 15273288 10.1073/pnas. 0403969101
35. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. AL McDoniels-Silvers CF Nimri GD Stoner RA Lubet M You, Clin Cancer Res 2002 8 1127 1138 11948124
36. Decorin suppresses lung metastases of murine osteosarcoma. K Shintani A Matsumine K Kusuzaki J Morikawa T Matsubara T Wakabayashi K Araki H Satonaka H Wakabayashi T Iino A Uchida, Oncol Rep 2008 19 1533 1539 18497961
37. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. C Ryk R Kumar RK Thirumaran SM Hou, Lung Cancer 2006 54 285 292 10.1016/j.lungcan.2006.08.004 17034901
38. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. MF López-Cima P González-Arriaga L García-Castro T Pascual MG Marrón XS Puente A Tardón, BMC Cancer 2007 7 162 17705814 10.1186/1471-2407-7-162
39. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. DA Weaver EL Crawford KA Warner F Elkhairi SA Khuder JC Willey, Mol Cancer 2005 4 18 15882455 10.1186/1476-4598-4-18